MONTREAL, April 19, 2007 (PRIME NEWSWIRE) -- Viropro Inc. (OTCBB:VPRO) ("Viropro") today provides an update to the financial community and to its shareholders regarding its March 19, 2007 announcement for the development of one of the company's main products, a targeted high volume sales Monoclonal Antibody.
